Patents by Inventor Paul Loadman
Paul Loadman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10912839Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.Type: GrantFiled: March 1, 2018Date of Patent: February 9, 2021Assignee: ELLIPSES PHARMA LIMITEDInventors: Robert Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
-
Publication number: 20200316212Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.Type: ApplicationFiled: June 19, 2020Publication date: October 8, 2020Inventors: Robert Andrew Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
-
Patent number: 10556014Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.Type: GrantFiled: March 16, 2018Date of Patent: February 11, 2020Assignee: ELLIPSES PHARMA LIMITEDInventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
-
Patent number: 10201622Abstract: The present inventors have harnessed the targeting of nanoparticles to tumor sites, combined with the tumor site specific elevated MMP-14 activity within one conjugate to simultaneously deliver a vascular disrupting agent (VDA) and a MRI contrast agent to a tumor site. The MMP activatable conjugate of the present invention provides both therapeutic and diagnostic functions—and is referred to as a “theranostic”. The theranostic conjugate of the present invention achieves the benefits of tumor site specificity, VDA delivery and MRI contrast agent delivery in a single theranostic conjugate. Consequently, the present invention provides a cancer “theranostic” which improves therapeutic efficacy while simultaneously reducing dose-limiting systemic toxicities and provides a tool for rapidly and non-invasively identifying tumor location, monitoring drug delivery and pharmacodynamics.Type: GrantFiled: July 25, 2014Date of Patent: February 12, 2019Assignees: The Trustees of The Leland Stanford Junior University, Incanthera LtdInventors: Paul Loadman, Robert Falconer, Jason Gill, Jianghong Rao, Heike E. Daldrup-Link
-
Publication number: 20190015519Abstract: The present invention harnesses the differential expression of membrane-type matrix metalloproteinases (MT-MMPs) between human solid tumours and normal tissues to provide a systemically inactive prodrug which is selectively activated at the tumour micro-environment. The present invention provides a prodrug which is a conjugate of a taxane and a selective MT-MMP cleavable delivery vehicle.Type: ApplicationFiled: November 29, 2016Publication date: January 17, 2019Inventors: Paul Loadman, Robert Falconer, Jason Gill
-
Publication number: 20180228910Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.Type: ApplicationFiled: March 16, 2018Publication date: August 16, 2018Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
-
Publication number: 20180177886Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.Type: ApplicationFiled: March 1, 2018Publication date: June 28, 2018Inventors: Robert Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
-
Patent number: 9956296Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.Type: GrantFiled: May 6, 2016Date of Patent: May 1, 2018Assignee: INCANTHERA LTDInventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
-
Patent number: 9937267Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.Type: GrantFiled: October 19, 2016Date of Patent: April 10, 2018Assignee: Incanthera LtdInventors: Robert Andrew Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
-
Publication number: 20170266307Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.Type: ApplicationFiled: October 19, 2016Publication date: September 21, 2017Inventors: Robert Andrew Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
-
Publication number: 20160303257Abstract: The present inventors have harnessed the targeting of nanoparticles to tumour sites, combined with the tumour site specific elevated MMP-14 activity within one conjugate to simultaneously deliver a vascular disrupting agent (VDA) and a MRI contrast agent to a tumour site. The MMP activatable conjugate of the present invention provides both therapeutic and diagnostic functions—and is referred to as a “theranostic”. The theranostic conjugate of the present invention achieves the benefits of tumour site specificity, VDA delivery and MRI contrast agent delivery in a single theranostic conjugate. Consequently, the present invention provides a cancer “theranostic” which improves therapeutic efficacy whilst simultaneously reducing dose-limiting systemic toxicities and provides a tool for rapidly and non-invasively identifying tumour location, monitoring drug delivery and pharmacodynamics.Type: ApplicationFiled: July 25, 2014Publication date: October 20, 2016Applicants: University of Bradford, The Trustees of the Leland Stanford Junior UniversityInventors: Paul Loadman, Robert Falconer, Jason Gill, Jianghong Rao, Heike E. Daldrup-Link
-
Publication number: 20160243252Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.Type: ApplicationFiled: May 6, 2016Publication date: August 25, 2016Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
-
Patent number: 9358303Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.Type: GrantFiled: December 17, 2013Date of Patent: June 7, 2016Assignee: Incanthera LtdInventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
-
Publication number: 20150196658Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.Type: ApplicationFiled: November 25, 2014Publication date: July 16, 2015Inventors: Robert Andrew Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
-
Patent number: 8927486Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a matrix metalloproteinase (MMP) proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.Type: GrantFiled: October 20, 2009Date of Patent: January 6, 2015Assignee: Incanthera LimitedInventors: Robert Falconer, Jason Gill, Jennifer Atkinson, Paul Loadman, Michael Bibby, Laurence Patterson
-
Publication number: 20140179592Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.Type: ApplicationFiled: December 17, 2013Publication date: June 26, 2014Applicant: INCANTHERA LIMITEDInventors: Jason Gill, Paul Loadman, Rob Falconer, Lawrence Patterson, Jennifer Atkinson, Michael Bibby
-
Patent number: 8691751Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.Type: GrantFiled: March 27, 2008Date of Patent: April 8, 2014Assignee: Incanthera LtdInventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Atkinson, Mike Bibby
-
Publication number: 20110275554Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.Type: ApplicationFiled: October 20, 2009Publication date: November 10, 2011Applicant: The University of BradfordInventors: Robert Andrew Falconer, Jason Gill, Jennifer Atkinson, Paul Loadman, Michael Bibby, Laurence Patterson
-
Publication number: 20100168036Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.Type: ApplicationFiled: March 27, 2008Publication date: July 1, 2010Applicant: University of BradfordInventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Atkinson, Mike Bibby